Patent US2304956A successfully refreshed from Google Patents.
Patent US2305310A successfully refreshed from Google Patents.
US4892935A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-human pulmonary carcinoma monoclonal antibody
Assignee: KH Neochem Co Ltd
•
Filing: 1987-07-06
•
Granted: 1990-01-09
•
Expires: 2007-07-06
Abstract
Abstract Monoclonal antibodies being capable of reacting with human squamous cell lung carcinoma, lung adenocarcinoma and large cell lung carcinoma, and non-reactive with human small cell lung carcinoma and normal human lung cells, and recognizing glycoproteins as antigens. Hybridomas having the characteristics of cell line SLC-454 secrete such antibodies. Method of diagnosing human lung cancer and method of therapeutic treatment are described.
Inventors
- 👤 Hajime Yoshida
- 👤 Nobuo Hanai
- 👤 Kenya Shitara
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 06:34
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3023; Y; Y10; Y10S; Y10S530/00; Y10S530/806; Y10S530/808; Y10S530/827; Y10S530/828; Y10S530/861
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
85 words
An anti-human pulmonary carcinoma antigen specific monoclonal antibody which has the same antigen specificity and binding characteristics as antibodies produced by hybridoma cell line ECACC 86070306, and which belongs to the class IgM, is capable of reacting with human squamous cell lung carcinoma, lung adenocarcinoma and large cell lung carcinoma; is non-reactive with human small cell lung carcinoma and normal human lung cell, and the binding activity of which is substantially unaffected with rabbit anti-β 2 microglobulin antibody, rabbit anti-CEA antibody and rabbit anti-AFP antibody.
Claim 2
Dependent Claim
85 words
An anti-human pulmonary carcinoma antigen specific monoclonal antibody which has the same antigen specificity and binding characteristics as antibodies produced by hybridoma cell line ECACC 86070306, and which belongs to the class IgM, is capable of reacting with human squamous cell lung carcinoma, lung adenocarcinoma and large cell lung carcinoma; is non-reactive with human small cell lung carcinoma and normal human lung cell, and the binding activity of which is substantially unaffected with rabbit anti-β 2 microglobulin antibody, rabbit anti-CEA antibody and rabbit anti-AFP antibody.
Claim 3
Dependent Claim
14 words
The monoclonal antibody according to claim 1, wherein the antibody is identified as SLC-454.
Claim 4
Dependent Claim
56 words
The monoclonal antibody according to claim 1, wherein the antibody is produced by cultivated a hybridoma cell line SLC-454 (ECACC 86070306) in a medium or administering the hybridoma to a mouse to thereby cause hybridoma cell propagation in the ascitic fluid in the mouse, followed by separation of the antibody from the culture or ascitic fluid.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-01-08 | 1993-07-10 | 1994-01-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-01-08 | 1997-07-10 | 1998-01-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-01-08 | 2001-07-10 | 2002-01-09 | $7700.00 | Window Closed / Lapsed |